Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
$1.48
$1.48
$0.63
$1.51
$60.83M1.25696,083 shsN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$11.10
-4.3%
$9.42
$2.20
$12.78
$304.03M-0.59191,166 shs15,296 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.68
-2.3%
$1.81
$1.32
$2.72
$245.35M1.71191,740 shs86,259 shs
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
$8.43
+2.2%
$5.23
$1.73
$10.43
$258.61M3.351.18 million shs521,102 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
0.00%0.00%0.00%0.00%+77.71%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%+25.63%+26.39%+55.09%+175.13%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.00%+4.27%-8.06%+20.42%-11.86%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
0.00%+3.49%+46.49%+319.85%+175.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.738 of 5 stars
4.43.00.00.02.62.50.6
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.97 of 5 stars
3.51.00.00.00.60.00.0
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
2.3974 of 5 stars
3.52.00.00.02.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
0.00
N/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.80
Moderate Buy$14.7532.88% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00316.67% Upside
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
3.00
Buy$26.60215.54% Upside

Current Analyst Ratings Breakdown

Latest ACHL, DBVT, SGMT, and IMMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$21.00
6/6/2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $27.00
5/29/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell$7.25
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/5/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $16.00
5/1/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/A$3.49 per shareN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$4.15M73.26N/AN/A$1.42 per share7.82
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M47.73N/AN/A$1.05 per share1.60
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
$2M129.27N/AN/A$5.08 per share1.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$113.92M-$4.92N/AN/AN/A-3,249.99%-278.24%-140.54%7/29/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-$45.57M-$1.76N/AN/AN/AN/A-35.21%-34.09%8/13/2025 (Estimated)

Latest ACHL, DBVT, SGMT, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.28N/AN/AN/A$0.64 millionN/A
5/8/2025Q1 2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-$0.79-$0.56+$0.23-$0.56N/AN/A
4/11/2025Q4 2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A-$1.10N/A-$1.10N/A$0.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
N/A
6.04
6.04
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
0.72
0.72
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
N/A
20.34
20.34

Institutional Ownership

CompanyInstitutional Ownership
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
56.38%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
87.86%

Insider Ownership

CompanyInsider Ownership
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
5.38%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.44%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achilles Therapeutics plc stock logo
ACHL
Achilles Therapeutics
25041.10 million38.89 millionNot Optionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million27.00 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
830.67 million26.17 millionOptionable

Recent News About These Companies

SGMT Sagimet Biosciences Inc. - Seeking Alpha
Sagimet Biosciences Inc. (SGMT) - Yahoo Finance
Sagimet Biosciences Inc.
Sagimet Biosciences Analyst Ratings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achilles Therapeutics stock logo

Achilles Therapeutics NASDAQ:ACHL

$1.48 0.00 (0.00%)
As of 03/26/2025

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$11.10 -0.50 (-4.31%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.68 -0.04 (-2.33%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Sagimet Biosciences stock logo

Sagimet Biosciences NASDAQ:SGMT

$8.43 +0.18 (+2.18%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.